https://www.thebodypro.com/author/treatment-action-group

Latest by Treatment Action Group

SMAC Mimetics and HIV Latency Img

SMAC Mimetics and HIV Latency

SMAC (second mitochondrial-derived activator of caspases) mimetics are a class of compounds that have recently entered clinical trials as potential cancer treatments, but also have potential against HIV.

Attempt to Oversell New Findings on Pyroptosis in HIV Infection Prompts Headline Debacle Img
News

Attempt to Oversell New Findings on Pyroptosis in HIV Infection Prompts Headline Debacle

A poorly conceived press release prompted some of the most egregiously inaccurate media headlines about HIV research in recent history.

Innate Immunity and HIV DNA Declines in Panobinostat Recipients Img

Innate Immunity and HIV DNA Declines in Panobinostat Recipients

Several measures of innate immunity were associated with the observed decrease of HIV DNA among a small study of patients patients taking panobinostat, an HIV latency reversing agent candidate, according to a recent analysis.

Perspectives on Post-Treatment Control of HIV Img

Perspectives on Post-Treatment Control of HIV

Several recent papers offer perspectives on the possibility of achieving post-treatment control of HIV replication by starting antiretroviral therapy during acute infection.

Mapping the HIV Integration Landscape: Cancer Genes and the Persistence of the Latent Reservoir Img
Cancer

Mapping the HIV Integration Landscape: Cancer Genes and the Persistence of the Latent Reservoir

Recently, in the journal Cell, a comprehensive analysis of HIV integration sites was published and the data argues against the idea that HIV targets cancer-associated genes as a means to persist; rather, integration into these genes is shown to be ...

Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial Img

Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper recently published in Nature describes encouraging results from a phase-1 trial in...

Novel, Broadly Active HIV Inhibitor Shows Potential for Vaccine Img

Novel, Broadly Active HIV Inhibitor Shows Potential for Vaccine

The inhibitor is designed to bind the HIV envelope at sites that attach to CD4 and CCR5 molecules on CD4 T cells; blocking this interaction prevents HIV from gaining entry and infecting the cell. It has currently shown high success in rhesus macaque ...

Lymphoid Tissue Fibrosis: New Studies and Candidate Therapies Img

Lymphoid Tissue Fibrosis: New Studies and Candidate Therapies

Study shows that HIV infection is associated with increased gut-associated lymphoid tissue (GALT) fibrosis and that "HIV suppression -- whether by [antiretroviral therapy] or in untreated elite controllers -- is insufficient to reverse or avert fibro...

HIV Reservoir Measurements and Viral Load Rebound After ART Interruption Img

HIV Reservoir Measurements and Viral Load Rebound After ART Interruption

To assist in the search for therapies that might contribute to curing HIV infection, scientists are seeking to identify biomarkers that are associated with control of viral load after an antiretroviral therapy (ART) interruption. If reliable predicto...

Stemming the Flow From HIV Reservoirs With Neutralizing Antibodies Img

Stemming the Flow From HIV Reservoirs With Neutralizing Antibodies

Two recent papers address the potential of broadly neutralizing antibodies (bNAbs) to decrease HIV rebound from persistent reservoirs. In the journal Cell, Ariel Halper-Stromberg and colleagues report the results of experiments conducted in the human...